Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Bacteria
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
many countries
|
| gptkbp:contraindication |
pregnancy
immunocompromised individuals |
| gptkbp:discoveredBy |
Germanier and colleagues
|
| gptkbp:discoveredIn |
1975
|
| gptkbp:form |
enteric-coated capsule
|
| gptkbp:geneticCharacteristic |
Vi antigen negative
galE mutation |
| gptkbp:marketedAs |
gptkb:Vivotif
|
| gptkbp:protectedBy |
typhoid fever
|
| gptkbp:regulates |
FDA approved
EMA approved |
| gptkbp:relatedTo |
gptkb:Salmonella_typhi_Ty2
|
| gptkbp:storage |
refrigerated
|
| gptkbp:subclassOf |
gptkb:Salmonella_enterica_serovar_Typhi
|
| gptkbp:usedFor |
typhoid vaccine
|
| gptkbp:vaccineType |
gptkb:live_attenuated_vaccine
|
| gptkbp:WHOStatus |
gptkb:World_Health_Organization_Model_List_of_Essential_Medicines
|
| gptkbp:bfsParent |
gptkb:Vivotif
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Salmonella typhi Ty21a
|